---
company: Moleculin Biotech, Inc.
ticker: MBRX
form: 8-K
filed: 2026-05-15
accession: 0001437749-26-017226
source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926017226/
---

# Moleculin Biotech (MBRX) earnings release, May 15, 2026

Moleculin Biotech, Inc. (MBRX) · Form 8-K, Item 2.02 · Filed 2026-05-15 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1659617/000143774926017226/)

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial

First interim unblinding expected in June 2026 following 45 subject enrollment milestone achieved in MIRACLE trial

Enrollment in MIRACLE trial continues to advance on pace with 90 th subject expected in Q3 2026

HOUSTON, May 15, 2026 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update.

“With enrollment now surpassing the first interim analysis threshold in the MIRACLE trial, we are just weeks away from beginning what we believe will be the most transformative period in the Company’s history. The impressive preliminary blinded remission data trend we reported earlier this year continues with the 45 subject blinded data. This trend supports our belief in Annamycin’s potential to meaningfully improve outcomes for patients with relapsed or refractory AML,” said Walter Klemp, Chairman and Chief Executive Officer of Moleculin.

“We also believe Annamycin has the potential to redefine the anthracycline class by addressing one of the most significant limitations of these foundational therapies, cardiotoxicity, while potentially expanding access to treatment options for patients who otherwise may not be eligible for standard anthracycline-based therapy due to current life-time dose limits,” Mr. Klemp added.

Recent Highlights

Clinical Development Update

Annamycin – MIRACLE Trial

Moleculin continues to advance the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) trial, a pivotal adaptive-design Phase 3 study evaluating AnnAraC in adult patients with relapsed or refractory AML.

Expected Milestones for Annamycin Development Program

Additional Pipeline Programs

Moleculin continues to support externally funded and investigator-sponsored studies involving WP1066 and other pipeline candidates targeting difficult-to-treat cancers and viral diseases.

First Quarter 2026 Financial Results

Research and development expenses for the three months ended March 31, 2026 and 2025 were $5.4 million and $3.4 million, respectively. The increase of $2.0 million is mainly related to the MIRACLE clinical trials in Europe of $1.4 million, additional nonclinical studies of $0.3 million and other research costs during the current quarter as compared to the prior year quarter.

General and administrative expenses for the quarter ended March 31, 2026 were approximately $2.5 million, compared with $2.5 million for the same period in 2025.

As of March 31, 2026, the Company had cash and cash equivalents of approximately $10.3 million. Management believes current cash resources, together with recent financing proceeds, will support planned operations into the third quarter of 2026.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (

M olecul i n

R

/R AML

A nnAraC

Cl inical

E valuation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”), for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on

X,

LinkedIn and

Facebook.

Forward-Looking Statements... (truncated)y has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:

JTC Team, LLC

Jenene Thomas

(908) 824-0775

MBRX@jtcir.com

## Financial statements

### Income Statement (Three Months Ended March 31, — MBRX@jtcir.com (in thousands, except share and per share amounts))

| | Three Months Ended March 31, – 2026 – $- | Three Months Ended March 31, – 2025 – $- |
|---|---:|---:|
| Operating expenses: | Research and development | 5,378 | 3,435 |
| Operating expenses: | General and administrative and depreciation and amortization | 2,496 | 2,508 |
| Operating expenses: | Total operating expenses | 7,874 | 5,943 |
| Operating expenses: | Loss from operations | -7,874 | -5,943 |
| Other income: | Gain from change in fair value of warrant liability | 10,770 |  |
| Other income: | Transaction costs allocated to warrant liabilities | -693 |  |
| Other income: | Loss on issuance of warrant liabilities | -15,158 |  |
| Other income: | Other income, net | 76 | 9 |
| Other income: | Interest income, net | 34 | 30 |
| Other income: | Net loss | -12,845 | -5,904 |
| Other income: | Warrant deemed dividend | -1,765 |  |
| Other income: | Net loss available to common stockholders | -14,610 | -5,904 |
| Other income: | Net loss per common share - basic and diluted | -3.54 | -15.8 |
| Other income: | Weighted average common shares outstanding - basic and diluted | 4,124,482 | 373,751 |

### Balance Sheet (March 31, 2026 — MBRX@jtcir.com (in thousands))

| | March 31, 2026 | December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 10,317 | 8,878 |
| Current assets: | Prepaid expenses and other current assets | 644 | 808 |
| Current assets: | Total current assets | 10,961 | 9,686 |
| Current assets: | Intangible assets | 11,148 | 11,148 |
| Current assets: | Other non-current assets | 900 | 900 |
| Current assets: | Operating lease right-of-use asset | 284 | 314 |
| Current assets: | Furniture and equipment, net | 70 | 78 |
| Current assets: | Total assets | 23,363 | 22,126 |
| Current liabilities: | Accounts payable and accrued expenses and other current liabilities | 7,962 | 6,854 |
| Current liabilities: | Total current liabilities | 7,962 | 6,854 |
| Current liabilities: | Operating lease liability - long-term, net of current portion | 185 | 222 |
| Current liabilities: | Warrant liability - long term | 33 | 44 |
| Current liabilities: | Total liabilities | 8,180 | 7,120 |
| Current liabilities: | Total stockholders' equity | 15,183 | 15,006 |
| Current liabilities: | Total liabilities and stockholders' equity | 23,363 | 22,126 |
